InVivo Therapeutics (NSDQ:NVIV) said today it enrolled yet another patient in the Inspire study of its neuro-spinal scaffold, bringing the total enrolled up to 17.
The Cambridge, Mass.-based company’s neuro-spinal scaffold is designed to be surgically implanted following acute spinal cord injuries to act as a physical substrate for nerve sprouting.
“We are pleased to hear that the patient is doing well. We now have 17 patients enrolled and in follow up, and with this patient marking the second enrollment in the last week, we remain enthusiastic about completing INSPIRE enrollment during the third quarter of this year,” CEO & chair Mark Perrin said in a press release.
The patient was enrolled at Philadelphia’s Thomas Jefferson University Hospital, the Cambridge, Mass.-based company said. The procedure was performed approximately 22 hours after the injury by Dr. James Harrop and principal site investigator Dr. Josh Heller.
“The surgery and implantation went smoothly and the patient is recovering well. We are excited to be part of The Inspire Study and we look forward to following and communicating the patient’s progress,” Dr. Harrop said in a prepared statement.
In May, InVivo said it would integrate data from the Christopher & Dana Reeve Foundation’s North American Clinical Trials Network Registry in the Contempo registry study which is complementing its ongoing Inspire study.
The company said that the Contempo study looks to provide comprehensive natural history benchmarks for the Inspire study of its neuro-spinal scaffold.
